The immune network in thyroid cancer

OncoImmunology

Volumn 5, Issue 6, 2016, Pages

  Galdiero, Maria Rosaria ^a   Varricchi, Gilda ^a   Marone, Gianni ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

Author keywords

Angiogenesis; chemokines; CXCL8 IL 8; dendritic cells; lymphangiogenesis; macrophages; mast cells; neutrophils; T reg cells; thyroid cancer

Indexed keywords

ANGIOPOIETIN; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 24; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

CANCER EPIDEMIOLOGY; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; GAMMA DELTA T LYMPHOCYTE; GENE EXPRESSION; HUMAN; IMMUNOSURVEILLANCE; LYMPHANGIOGENESIS; LYMPHOID CELL; MAST CELL; MOLECULAR PATHOLOGY; NATURAL KILLER CELL; NATURAL KILLER T CELL; NEUTROPHIL; NONHUMAN; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SUPPRESSOR CELL; TH17 CELL; THYROID CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84974809090     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1168556     Document Type: Review

References (117)

1. A.Mantovani, P.Allavena, A.Sica, F.Balkwill. Cancer-related inflammation. Nature 2008; 454:436-44; PMID:18650914; 10.1038/nature07205
2. L.Zitvogel, L.Apetoh, F.Ghiringhelli, F.Andre, A.Tesniere, G.Kroemer. The anticancer immune response: indispensable for therapeutic success? J Clin Invest 2008; 118:1991-2001; PMID:18523649; 10.1172/JCI35180
3. V.Shankaran, H.Ikeda, A.T.Bruce, J.M.White, P.E.Swanson, L.J.Old, R.D.Schreiber. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410:1107-11; PMID:11323675; 10.1038/35074122
4. L.L.Cunha, M.A.Marcello, L.S.Ward. The role of the inflammatory microenvironment in thyroid carcinogenesis. Endocrine-related cancer 2014; 21:R85-R103; PMID:24302667; 10.1530/ERC-13-0431
5. T.Carling, R.Udelsman. Thyroid cancer. Ann Rev Med 2014; 65:125-37; PMID:24274180; 10.1146/annurev-med-061512-105739
6. S.J.Hsiao, Y.E.Nikiforov. Molecular approaches to thyroid cancer diagnosis. Endocrine-related cancer 2014; 21:T301-13; PMID:24829266; 10.1530/ERC-13-0165
7. Cancer Genome Atlas Research N. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014; 159:676-90; PMID:25417114; 10.1016/j.cell.2014.09.050
8. C.Garlanda, C.A.Dinarello, A.Mantovani. The interleukin-1 family: back to the future. Immunity 2013; 39:1003-18; PMID:24332029; 10.1016/j.immuni.2013.11.010
9. A.P.Weetman, G.L.Bennett, W.L.Wong. Thyroid follicular cells produce interleukin-8. J Clin Endocrinol Metab 1992; 75:328-30; PMID:1619027; 10.1210/jcem.75.1.1619027\
10. M.Kammoun-Krichen, N.Bougacha-Elleuch, M.Mnif, F.Bougacha, I.Charffedine, S.Rebuffat, A.Rebai, E.Glasson, M.Abid, F.Ayadi et al. IL-1beta a potential factor for discriminating between thyroid carcinoma and atrophic thyroiditis. Eur Cytokine Netw 2012; 23:101-6; PMID:22995155; 10.1684/ecn.2012.0312
11. S.J.Van Dyken, R.M.Locksley. Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Ann Rev Immunol 2013; 31:317-43; PMID:23298208; 10.1146/annurev-immunol-032712-095906
12. A.Genovese, G.Borgia, L.Bjorck, A.Petraroli, A.de Paulis, M.Piazza, G.Marone. Immunoglobulin superantigen protein L induces IL-4 and IL-13 secretion from human Fc epsilon RI+ cells through interaction with the kappa light chains of IgE. J Immunol 2003; 170:1854-61; PMID:12574351; 10.4049/jimmunol.170.4.1854
13. A.Mantovani, S.K.Biswas, M.R.Galdiero, A.Sica, M.Locati. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol 2013; 229:176-85; PMID:23096265; 10.1002/path.4133
14. M.Ryder, M.Gild, T.M.Hohl, E.Pamer, J.Knauf, R.Ghossein, J.A.Joyce, J.A.Fagin. Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression. PloS one 2013; 8:e54302; PMID:23372702; 10.1371/journal.pone.0054302
15. R.Ameziane-El-Hassani, M.Talbot, M.C.de Souza Dos Santos, A.Al Ghuzlan, D.Hartl, J.M.Bidart, X.De Deken, F.Miot, I.Diallo, F.de Vathaire et al. NADPH oxidase DUOX1 promotes long-term persistence of oxidative stress after an exposure to irradiation. Proc Natl Acad Sci U S A 2015; 112:5051-6; PMID:25848056; 10.1073/pnas.1420707112
16. M.H.Mannino, Z.Zhu, H.Xiao, Q.Bai, M.R.Wakefield, Y.Fang. The paradoxical role of IL-10 in immunity and cancer. Cancer letters 2015; 367:103-7; PMID:26188281; 10.1016/j.canlet.2015.07.009
17. C.Li, H.Li, K.Jiang, J.Li, X.Gai. TLR4 signaling pathway in mouse Lewis lung cancer cells promotes the expression of TGF-beta1 and IL-10 and tumor cells migration. Bio-medical materials and engineering 2014; 24:869-75; PMID:24211974; 10.3233/BME-130879
18. H.Yu, X.Huang, X.Liu, H.Jin, G.Zhang, Q.Zhang, J.Yu. Regulatory T cells and plasmacytoid dendritic cells contribute to the immune escape of papillary thyroid cancer coexisting with multinodular non-toxic goiter. Endocrine 2013; 44:172-81; PMID:23264145; 10.1007/s12020-012-9853-2
19. M.Todaro, M.Zerilli, L.Ricci-Vitiani, M.Bini, M.Perez Alea, A.Maria Florena, L.Miceli, G.Condorelli, S.Bonventre, G.Di Gesu et al. Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells. Cancer Res 2006; 66:1491-9; PMID:16452205; 10.1158/0008-5472.CAN-05-2514
20. G.Stassi, M.Todaro, M.Zerilli, L.Ricci-Vitiani, D.Di Liberto, M.Patti, A.Florena, F.Di Gaudio, G.Di Gesu, R.De Maria. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res 2003; 63:6784-90; PMID:14583474
21. M.Akdis, S.Burgler, R.Crameri, T.Eiwegger, H.Fujita, E.Gomez, S.Klunker, N.Meyer, L.O'Mahony, O.Palomares et al. Interleukins, from 1 to 37, and interferon-gamma: receptors, functions, and roles in diseases. J Allergy Clin Immunol 2011; 127:701-21 e1-70; PMID:21377040; 10.1016/j.jaci.2010.11.050
22. S.Shinohara, J.L.Rothstein. Interleukin 24 is induced by the RET/PTC3 oncoprotein and is an autocrine growth factor for epithelial cells. Oncogene 2004; 23:7571-9; PMID:15326486; 10.1038/sj.onc.1207964
23. C.A.Hunter, S.A.Jones. IL-6 as a keystone cytokine in health and disease. Nat Immunol 2015; 16:448-57; PMID:25898198; 10.1038/ni.3153
24. R.M.Melillo, V.Guarino, E.Avilla, M.R.Galdiero, F.Liotti, N.Prevete, F.W.Rossi, F.Basolo, C.Ugolini, A.de Paulis et al. Mast cells have a protumorigenic role in human thyroid cancer. Oncogene 2010; 29:6203-15; PMID:20729915; 10.1038/onc.2010.348
25. C.Visciano, F.Liotti, N.Prevete, G.Cali, R.Franco, F.Collina, A.de Paulis, G.Marone, M.Santoro, R.M.Melillo. Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway. Oncogene 2015; 34:5175-86; PMID:25619830; 10.1038/onc.2014.441
26. R.A.Flavell, S.Sanjabi, S.H.Wrzesinski, P.Licona-Limon. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 2010; 10:554-67; PMID:20616810; 10.1038/nri2808
27. J.A.Knauf, M.A.Sartor, M.Medvedovic, E.Lundsmith, M.Ryder, M.Salzano, Y.E.Nikiforov, T.J.Giordano, R.A.Ghossein, J.A.Fagin. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFbeta signaling. Oncogene 2011; 30:3153-62; PMID:21383698; 10.1038/onc.2011.44
28. C.Eloy, J.Santos, J.Cameselle-Teijeiro, P.Soares, M.Sobrinho-Simoes. TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma. Virchows Arch 2012; 460:587-600; PMID:22527019; 10.1007/s00428-012-1234-y
29. G.Jiang, S.Ma, Y.Wei, Y.Wu, X.Yu, H.Liu. The prevalence and distribution of Th17 and Tc17 cells in patients with thyroid tumor. Immunology letters 2014; 162:68-73; PMID:25068436; 10.1016/j.imlet.2014.07.005
30. Y.C.Lee, J.H.Chung, S.K.Kim, S.Y.Rhee, S.Chon, S.J.Oh, I.K.Hong, Y.G.Eun. Association between interleukin 17/interleukin 17 receptor gene polymorphisms and papillary thyroid cancer in Korean population. Cytokine 2015; 71:283-8; PMID:25484349; 10.1016/j.cyto.2014.11.011
31. S.Crotty. A brief history of T cell help to B cells. Nat Rev Immunol 2015; 15:185-9; PMID:25677493; 10.1038/nri3803
32. R.Purwar, C.Schlapbach, S.Xiao, H.S.Kang, W.Elyaman, X.Jiang, A.M.Jetten, S.J.Khoury, R.C.Fuhlbrigge, V.K.Kuchroo et al. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med 2012; 18:1248-53; PMID:22772464; 10.1038/nm.2856
33. M.Xiao, S.Hu, J.Tang, L.Zhang, H.Jiang. Interleukin (IL)-21 promoter polymorphism increases the risk of thyroid cancer in Chinese population. Gene 2014; 537:15-9; PMID:24389496; 10.1016/j.gene.2013.12.050
34. L.Zitvogel, L.Galluzzi, O.Kepp, M.J.Smyth, G.Kroemer. Type I interferons in anticancer immunity. Nat Rev Immunol 2015; 15:405-14; PMID:26027717; 10.1038/nri3845
35. G.Schiavoni, F.Mattei, L.Gabriele. Type I Interferons as Stimulators of DC-Mediated Cross-Priming: Impact on Anti-Tumor Response. Front Immunol 2013; 4:483; PMID:24400008; 10.3389/fimmu.2013.00483
36. T.E.Angell, M.G.Lechner, J.K.Jang, J.S.LoPresti, A.L.Epstein. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res 2014; 20:6034-44; PMID:25294906; 10.1158/1078-0432.CCR-14-0879
37. D.Bosisio, V.Salvi, V.Gagliostro, S.Sozzani. Angiogenic and antiangiogenic chemokines. Chem Immunol Allergy 2014; 99:89-104; PMID:24217604; 10.1159/000353317
38. R.M.Melillo, M.D.Castellone, V.Guarino, V.De Falco, A.M.Cirafici, G.Salvatore, F.Caiazzo, F.Basolo, R.Giannini, M.Kruhoffer et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005; 115:1068-81; PMID:15761501; 10.1172/JCI200522758
39. M.G.Borrello, L.Alberti, A.Fischer, D.Degl'innocenti, C.Ferrario, M.Gariboldi, F.Marchesi, P.Allavena, A.Greco, P.Collini et al. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci U S A 2005; 102:14825-30; PMID:16203990; 10.1073/pnas.0503039102
40. M.Rotondi, F.Coperchini, L.Chiovato. CXCL8 in thyroid disease: from basic notions to potential applications in clinical practice. Cytokine & growth factor reviews 2013; 24:539-46; PMID:24011840; 10.1016/j.cytogfr.2013.08.001
41. A.Antonelli, S.M.Ferrari, P.Fallahi, S.Piaggi, A.Di Domenicantonio, D.Galleri, L.Santarpia, F.Basolo, E.Ferrannini, P.Miccoli. Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer. Cytokine 2012; 59:218-22; PMID:22633083; 10.1016/j.cyto.2012.04.042
42. M.Rotondi, F.Coperchini, P.Pignatti, F.Magri, L.Chiovato. Metformin reverts the secretion of CXCL8 induced by TNF-alpha in primary cultures of human thyroid cells: an additional indirect anti-tumor effect of the drug. J Clin Endocrinol Metab 2015; 100:E427-32; PMID:25590211; 10.1210/jc.2014-3045
43. M.Muzza, D.Degl'Innocenti, C.Colombo, M.Perrino, E.Ravasi, S.Rossi, V.Cirello, P.Beck-Peccoz, M.G.Borrello, L.Fugazzola. The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. Clin Endocrinol 2010; 72:702-8; PMID:20447069; 10.1111/j.1365-2265.2009.03699.x
44. K.T.Bauerle, R.E.Schweppe, G.Lund, G.Kotnis, G.Deep, R.Agarwal, N.Pozdeyev, W.M.Wood, B.R.Haugen. Nuclear factor kappaB-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8. J Clin Endocrinol Metab 2014; 99:E1436-44; PMID:24758177; 10.1210/jc.2013-3636
45. W.Fang, L.Ye, L.Shen, J.Cai, F.Huang, Q.Wei, X.Fei, X.Chen, H.Guan, W.Wang et al. Tumor-associated macrophages promote the metastatic potential of thyroid papillary cancer by releasing CXCL8. Carcinogenesis 2014; 35:1780-7; PMID:24608042; 10.1093/carcin/bgu060
46. A.Antonelli, S.M.Ferrari, P.Fallahi, S.Frascerra, S.Piaggi, S.Gelmini, C.Lupi, M.Minuto, P.Berti, S.Benvenga et al. Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists. Endocrine-related cancer 2009; 16:1299-311; PMID:19755523; 10.1677/ERC-08-0337
47. Z.Liu, D.X.Sun, X.Y.Teng, W.X.Xu, X.P.Meng, B.S.Wang. Expression of stromal cell-derived factor 1 and CXCR7 in papillary thyroid carcinoma. Endocrine Pathol 2012; 23:247-53; PMID:23070788; 10.1007/s12022-012-9223-x
48. S.Y.Chung, E.S.Park, S.Y.Park, J.Y.Song, H.S.Ryu. CXC motif ligand 12 as a novel diagnostic marker for papillary thyroid carcinoma. Head & neck 2014; 36:1005-12; PMID:23784811; 10.1002/hed.23404
49. Z.Liu, L.Yang, X.Teng, H.Zhang, H.Guan. The involvement of CXCR7 in modulating the progression of papillary thyroid carcinoma. J Surg Res 2014; 191:379-88; PMID:24814201; 10.1016/j.jss.2014.04.016
50. W.Zeng, H.Chang, M.Ma, Y.Li. CCL20/CCR6 promotes the invasion and migration of thyroid cancer cells via NF-kappa B signaling-induced MMP-3 production. Exp Mol Pathol 2014; 97:184-90; PMID:24984269; 10.1016/j.yexmp.2014.06.012
51. C.Passaro, F.Borriello, V.Vastolo, S.D.Somma, E.Scamardella, V.Gigantino, R.Franco, G.Marone, G.Portella. The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma. Oncotarget 2015; 7(2):1500-15; PMID:26625205; 10.18632/oncotarget.6430
52. S.Loffredo, R.I.Staiano, F.Granata, A.Genovese, G.Marone. Immune cells as a source and target of angiogenic and lymphangiogenic factors. In: Marone G, Granata F, eds. Angiogenesis, Lymphangiogenesis and Clinical Implications Chem Immunol Allergy. Basel: Karger 2014; 99:15-36; PMID:24217601; 10.1159/000353316
53. A.Detoraki, R.I.Staiano, F.Granata, G.Giannattasio, N.Prevete, A.de Paulis, D.Ribatti, A.Genovese, M.Triggiani, G.Marone. Vascular endothelial growth factors synthesized by human lung mast cells exert angiogenic effects. J Allergy Clin Immunol 2009; 123:1142-9, PMID:19275959; 10.1016/j.jaci.2009.01.044
54. F.Granata, A.Frattini, S.Loffredo, R.I.Staiano, A.Petraroli, D.Ribatti, R.Oslund, M.H.Gelb, G.Lambeau, G.Marone et al. Production of vascular endothelial growth factors from human lung macrophages induced by group IIA and group X secreted phospholipases A2. J Immunol 2010; 184:5232-41; PMID:20357262; 10.4049/jimmunol.0902501
55. A.Bruno, C.Focaccetti, A.Pagani, A.S.Imperatori, M.Spagnoletti, N.Rotolo, A.R.Cantelmo, F.Franzi, C.Capella, G.Ferlazzo et al. The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer. Neoplasia 2013; 15:133-42; PMID:23441128; 10.1593/neo.121758
56. T.J.Curiel, P.Cheng, P.Mottram, X.Alvarez, L.Moons, M.Evdemon-Hogan, S.Wei, L.Zou, I.Kryczek, G.Hoyle et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res 2004; 64:5535-8; PMID:15313886; 10.1158/0008-5472.CAN-04-1272
57. A.H.Nissim Ben Efraim, F.Levi-Schaffer. Roles of Eosinophils in the Modulation of Angiogenesis. In: G.Marone, F.Granata, eds. Angiogenesis, Lymphangiogenesis and Clinical Implications. Chem Immunol Allergy. Basel: Karger, 2014:138-54.
58. J.Shiraishi, H.Koyama, M.Seki, M.Hatayama, M.Naka, M.Kurajoh, H.Okazaki, T.Shoji, Y.Moriwaki, T.Yamamoto et al. Anaplastic thyroid carcinoma accompanied by uncontrollable eosinophilia. Internal medicine 2015; 54:611-6; PMID:25786451; 10.2169/internalmedicine.54.3446
59. A.Facciabene, X.Peng, I.S.Hagemann, K.Balint, A.Barchetti, L.P.Wang, P.A.Gimotty, C.B.Gilks, P.Lal, L.Zhang et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011; 475:226-30; PMID:21753853; 10.1038/nature10169
60. C.Murdoch, M.Muthana, S.B.Coffelt, C.E.Lewis. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008; 8:618-31; PMID:18633355; 10.1038/nrc2444
61. M.De Palma, M.A.Venneri, R.Galli, L.Sergi Sergi, L.S.Politi, M.Sampaolesi, L.Naldini. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer cell 2005; 8:211-26; PMID:16169466; 10.1016/j.ccr.2005.08.002
62. A.de Paulis, N.Prevete, I.Fiorentino, F.W.Rossi, S.Staibano, N.Montuori, P.Ragno, A.Longobardi, B.Liccardo, A.Genovese et al. Expression and functions of the vascular endothelial growth factors and their receptors in human basophils. J Immunol 2006; 177:7322-31; PMID:17082651; 10.4049/jimmunol.177.10.7322
63. M.J.Bissell, W.C.Hines. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011; 17:320-9; PMID:21383745; 10.1038/nm.2328
64. L.M.Coussens, L.Zitvogel, A.K.Palucka. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science New York, NY 2013; 339:286-91; PMID:23329041; 10.1126/science.1232227
65. M.R.Galdiero, C.Garlanda, S.Jaillon, G.Marone, A.Mantovani. Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol 2013; 228:1404-12; PMID:23065796; 10.1002/jcp.24260
66. M.Ryder, R.A.Ghossein, J.C.Ricarte-Filho, J.A.Knauf, J.A.Fagin. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocrine-related cancer 2008; 15:1069-74; PMID:18719091; 10.1677/ERC-08-0036
67. S.Kim, S.W.Cho, H.S.Min, K.M.Kim, G.J.Yeom, E.Y.Kim, K.E.Lee, Y.G.Yun, J.Park do, Y.J.Park. The expression of tumor-associated macrophages in papillary thyroid carcinoma. Endocrinol Metab 2013; 28:192-8; PMID:24396678; 10.3803/EnM.2013.28.3.192
68. K.Y.Jung, S.W.Cho, Y.A.Kim, D.Kim, B.C.Oh, J.Park do, Y.J.Park. Cancers with Higher Density of Tumor-Associated Macrophages Were Associated with Poor Survival Rates. J Pathol Transl Med 2015; 49:318-24; PMID:26081823; 10.4132/jptm.2015.06.01
69. B.Caillou, M.Talbot, U.Weyemi, C.Pioche-Durieu, A.Al Ghuzlan, J.M.Bidart, S.Chouaib, M.Schlumberger, C.Dupuy. Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma. PLoS One 2011; 6:e22567; PMID:21811634; 10.1371/journal.pone.0022567
70. W.C.Chang, J.Y.Chen, C.H.Lee, A.H.Yang. Expression of decoy receptor 3 in diffuse sclerosing variant of papillary thyroid carcinoma: correlation with M2 macrophage differentiation and lymphatic invasion. Thyroid 2013; 23:720-6; PMID:23186064; 10.1089/thy.2012.0261
71. W.Qing, W.Y.Fang, L.Ye, L.Y.Shen, X.F.Zhang, X.C.Fei, X.Chen, W.Q.Wang, X.Y.Li, J.C.Xiao et al. Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma. Thyroid 2012; 22:905-10; PMID:22870901; 10.1089/thy.2011.0452
72. A.M.Dudek, S.Martin, A.D.Garg, P.Agostinis. Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity. Front Immunol 2013; 4:438; PMID:24376443; 10.3389/fimmu.2013.00438
73. O.Hilly, R.Koren, R.Raz, L.Rath-Wolfson, A.Mizrachi, Y.Hamzany, G.Bachar, T.Shpitzer. The role of s100-positive dendritic cells in the prognosis of papillary thyroid carcinoma. Am J Clin Pathol 2013; 139:87-92; PMID:23270903; 10.1309/AJCPAKYDO56NKMYZ
74. S.Scarpino, A.Stoppacciaro, F.Ballerini, M.Marchesi, M.Prat, M.C.Stella, S.Sozzani, P.Allavena, A.Mantovani, L.P.Ruco. Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells. Am J Pathol 2000; 156:831-7; PMID:10702399; 10.1016/S0002-9440(10)64951-6
75. K.Tsuge, H.Takeda, S.Kawada, K.Maeda, M.Yamakawa. Characterization of dendritic cells in differentiated thyroid cancer. J Pathol 2005; 205:565-76; PMID:15714595; 10.1002/path.1731
76. C.Ugolini, F.Basolo, A.Proietti, P.Vitti, R.Elisei, P.Miccoli, A.Toniolo. Lymphocyte and immature dendritic cell infiltrates in differentiated, poorly differentiated, and undifferentiated thyroid carcinoma. Thyroid 2007; 17:389-93; PMID:17542668; 10.1089/thy.2006.0306
77. G.Marone, S.J.Galli, Y.Kitamura. Probing the roles of mast cells and basophils in natural and acquired immunity, physiology and disease. Trends Immunol 2002; 23:425-7; PMID:12200056; 10.1016/S1471-4906(02)02274-3
78. G.Marone, G.Varricchi, S.Loffredo, F.Granata. Mast cells and basophils in inflammatory and tumor angiogenesis and lymphangiogenesis. Eur J Pharmacol 2015; 778:146-51; PMID:25941082; 10.1016/j.ejphar.2015.03.088.
79. A.Proietti, C.Ugolini, R.M.Melillo, G.Crisman, R.Elisei, M.Santoro, M.Minuto, P.Vitti, P.Miccoli, F.Basolo. Higher intratumoral expression of CD1a, tryptase, and CD68 in a follicular variant of papillary thyroid carcinoma compared to adenomas: correlation with clinical and pathological parameters. Thyroid 2011; 21:1209-15; PMID:22007938; 10.1089/thy.2011.0059
80. A.Detoraki, F.Granata, S.Staibano, F.W.Rossi, G.Marone, A.Genovese. Angiogenesis and lymphangiogenesis in bronchial asthma. Allergy 2010; 65:946-58; PMID:20415716; 10.1111/j.1398-9995.2010.02372.x
81. S.Jaillon, M.R.Galdiero, D.Del Prete, M.A.Cassatella, C.Garlanda, A.Mantovani. Neutrophils in innate and adaptive immunity. Semin Immunopathol 2013; 35:377-94; PMID:23553214; 10.1007/s00281-013-0374-8
82. Z.G.Fridlender, J.Sun, S.Kim, V.Kapoor, G.Cheng, L.Ling, G.S.Worthen, S.M.Albelda. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell 2009; 16:183-94; PMID:19732719; 10.1016/j.ccr.2009.06.017
83. I.Bhatti, O.Peacock, G.Lloyd, M.Larvin, R.I.Hall. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg 2010; 200:197-203; PMID:20122680; 10.1016/j.amjsurg.2009.08.041
84. C.L.Liu, J.J.Lee, T.P.Liu, Y.C.Chang, Y.C.Hsu, S.P.Cheng. Blood neutrophil-to-lymphocyte ratio correlates with tumor size in patients with differentiated thyroid cancer. J Surg Oncol 2013; 107:493-7; PMID:22996403; 10.1002/jso.23270
85. C.Seretis, S.Gourgiotis, G.Gemenetzis, F.Seretis, E.Lagoudianakis, G.Dimitrakopoulos. The significance of neutrophil/lymphocyte ratio as a possible marker of underlying papillary microcarcinomas in thyroidal goiters: a pilot study. Am J Surg 2013; 205:691-6; PMID:23388425; 10.1016/j.amjsurg.2012.08.006
86. B.H.Lang, C.P.Ng, K.B.Au, K.P.Wong, K.K.Wong, K.Y.Wan. Does preoperative neutrophil lymphocyte ratio predict risk of recurrence and occult central nodal metastasis in papillary thyroid carcinoma? World journal of surgery 2014; 38:2605-12; PMID:24809487; 10.1007/s00268-014-2630-z
87. J.S.Cho, M.H.Park, Y.J.Ryu, J.H.Yoon. The neutrophil to lymphocyte ratio can discriminate anaplastic thyroid cancer against poorly or well differentiated cancer. Annals of surgical treatment and research 2015; 88:187-92; PMID:25844352; 10.4174/astr.2015.88.4.187
88. J.I.Youn, D.I.Gabrilovich. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 2010; 40:2969-75; PMID:21061430; 10.1002/eji.201040895
89. S.Suzuki, M.Shibata, K.Gonda, Y.Kanke, M.Ashizawa, D.Ujiie, S.Suzushino, K.Nakano, T.Fukushima, K.Sakurai et al. Immunosuppression involving increased myeloid-derived suppressor cell levels, systemic inflammation and hypoalbuminemia are present in patients with anaplastic thyroid cancer. Mol Clin Oncol 2013; 1:959-64; PMID:24649277; 10.3892/mco.2013.170
90. L.L.Cunha, E.C.Morari, A.C.Guihen, D.Razolli, R.Gerhard, S.Nonogaki, F.A.Soares, J.Vassallo, L.S.Ward. Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma. Clin Endocrinol 2012; 77:918-25; PMID:22738343; 10.1111/j.1365-2265.2012.04482.x
91. S.Solito, I.Marigo, L.Pinton, V.Damuzzo, S.Mandruzzato, V.Bronte. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci 2014; 1319:47-65; PMID:24965257; 10.1111/nyas.12469
92. F.Wang, Z.Tian, H.Wei. Genomic expression profiling of NK cells in health and disease. Eur J Immunol 2015; 45:661-78; PMID:25476835; 10.1002/eji.201444998
93. F.Gogali, G.Paterakis, G.Z.Rassidakis, G.Kaltsas, C.I.Liakou, P.Gousis, E.Neonakis, M.N.Manoussakis, C.Liapi. Phenotypical analysis of lymphocytes with suppressive and regulatory properties (Tregs) and NK cells in the papillary carcinoma of thyroid. J Clin Endocrinol Metab 2012; 97:1474-82; PMID:22399513; 10.1210/jc.2011-1838
94. F.Gogali, G.Paterakis, G.Z.Rassidakis, C.I.Liakou, C.Liapi. CD3(−)CD16(−)CD56(bright) immunoregulatory NK cells are increased in the tumor microenvironment and inversely correlate with advanced stages in patients with papillary thyroid cancer. Thyroid 2013; 23:1561-8; PMID:23721357; 10.1089/thy.2012.0560
95. E.Wennerberg, A.Pfefferle, L.Ekblad, Y.Yoshimoto, V.Kremer, V.O.Kaminskyy, C.C.Juhlin, A.Hoog, I.Bodin, V.Svjatoha et al. Human anaplastic thyroid carcinoma cells are sensitive to NK cell-mediated lysis via ULBP2/5/6 and chemoattract NK cells. Clin Cancer Res 2014; 20:5733-44; PMID:25212604; 10.1158/1078-0432.CCR-14-0291
96. R.S.Parhar, M.Zou, F.A.Al-Mohanna, E.Y.Baitei, A.M.Assiri, B.F.Meyer, Y.Shi. IL-12 immunotherapy of Braf(V600E)-induced papillary thyroid cancer in a mouse model. Lab Invest 2016; 96:89-97; PMID:26501867; 10.1038/labinvest.2015.126
97. F.C.Robertson, J.A.Berzofsky, M.Terabe. NKT cell networks in the regulation of tumor immunity. Front Immunol 2014; 5:543; PMID:25389427; 10.3389/fimmu.2014.00543
98. Y.Ma, L.Aymeric, C.Locher, S.R.Mattarollo, N.F.Delahaye, P.Pereira, L.Boucontet, L.Apetoh, F.Ghiringhelli, N.Casares et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med 2011; 208:491-503; PMID:21383056; 10.1084/jem.20100269
99. D.Artis, H.Spits. The biology of innate lymphoid cells. Nature 2015; 517:293-301; PMID:25592534; 10.1038/nature14189
100. M.Eisenring, J.vom Berg, G.Kristiansen, E.Saller, B.Becher. IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat Immunol 2010; 11:1030-8; PMID:20935648; 10.1038/ni.1947
101. J.H.Russell, T.J.Ley. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002; 20:323-70; PMID:11861606; 10.1146/annurev.immunol.20.100201.131730
102. L.L.Cunha, M.A.Marcello, S.Nonogaki, E.C.Morari, F.A.Soares, J.Vassallo, L.S.Ward. CD8+ tumour-infiltrating lymphocytes and COX2 expression may predict relapse in differentiated thyroid cancer. Clin Endocrinol 2015; 83:246-53; PMID:25130519; 10.1111/cen.12586
103. T.E.Angell, M.G.Lechner, J.K.Jang, A.J.Correa, J.S.LoPresti, A.L.Epstein. BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid 2014; 24:1385-93; PMID:24955518; 10.1089/thy.2014.0134
104. B.Ruffell, D.G.DeNardo, N.I.Affara, L.M.Coussens. Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev 2010; 21:3-10; PMID:20005150; 10.1016/j.cytogfr.2009.11.002
105. S.A.Quezada, T.R.Simpson, K.S.Peggs, T.Merghoub, J.Vider, X.Fan, R.Blasberg, H.Yagita, P.Muranski, P.A.Antony et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010; 207:637-50; PMID:20156971; 10.1084/jem.20091918
106. S.Imam, R.Paparodis, D.Sharma, J.C.Jaume. Lymphocytic profiling in thyroid cancer provides clues for failure of tumor immunity. Endocrine-related cancer 2014; 21:505-16; PMID:24623740; 10.1530/ERC-13-0436
107. D.Wolf, S.Sopper, A.Pircher, G.Gastl, A.M.Wolf. Treg(s) in Cancer: Friends or Foe? J Cell Physiol 2015; 230:2598-605; PMID:25913194; 10.1002/jcp.25016
108. J.D.French, G.R.Kotnis, S.Said, C.D.Raeburn, R.C.McIntyre, Jr, J.P.Klopper, B.R.Haugen. Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. J Clin Endocrinol Metab 2012; 97:E934-43; PMID:22466343; 10.1210/jc.2011-3428
109. J.D.French, Z.J.Weber, D.L.Fretwell, S.Said, J.P.Klopper, B.R.Haugen. Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab 2010; 95:2325-33; PMID:20207826; 10.1210/jc.2009-2564
110. H.S.Ryu, Y.S.Park, H.J.Park, Y.R.Chung, C.K.Yom, S.H.Ahn, Y.J.Park, S.H.Park, S.Y.Park. Expression of indoleamine 2,3-dioxygenase and infiltration of FOXP3+ regulatory T cells are associated with aggressive features of papillary thyroid microcarcinoma. Thyroid 2014; 24:1232-40; PMID:24742251; 10.1089/thy.2013.0423
111. C.Gu-Trantien, S.Loi, S.Garaud, C.Equeter, M.Libin, A.de Wind, M.Ravoet, H.Le Buanec, C.Sibille, G.Manfouo-Foutsop et al. CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 2013; 123:2873-92; PMID:23778140; 10.1172/JCI67428
112. M.H.Kaplan, M.M.Hufford, M.R.Olson. The development and in vivo function of T helper 9 cells. Nat Rev Immunol 2015; 15:295-307; PMID:25848755; 10.1038/nri3824
113. F.Vegran, H.Berger, R.Boidot, G.Mignot, M.Bruchard, M.Dosset, F.Chalmin, C.Rebe, V.Derangere, B.Ryffel et al. The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells. Nat Immunol 2014; 15:758-66; PMID:24973819; 10.1038/ni.2925
114. S.M.Ferrari, P.Fallahi, U.Politti, G.Materazzi, E.Baldini, S.Ulisse, P.Miccoli, A.Antonelli. Molecular Targeted Therapies of Aggressive Thyroid Cancer. Front Endocrinol 2015; 6:176; PMID:26635725; 10.3389/fendo.2015.00176
115. G.Germano, R.Frapolli, M.Simone, M.Tavecchio, E.Erba, S.Pesce, F.Pasqualini, F.Grosso, R.Sanfilippo, P.G.Casali et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res 2010; 70:2235-44; PMID:20215499; 10.1158/0008-5472.CAN-09-2335
116. K.T.Wright, C.Giardina, A.T.Vella. Therapeutic targeting of the inflammome. Biochem Pharmacol 2014; 92:184-91; PMID:25204592; 10.1016/j.bcp.2014.08.027
117. L.T.Nguyen, P.S.Ohashi. Clinical blockade of PD1 and LAG3–potential mechanisms of action. Nat Rev Immunol 2015; 15:45-56; PMID:25534622; 10.1038/nri3790